How do you advise scheduling follow-up visits for patients on tirbanibulin, knowing pivotal trial endpoints extended to 57 days?

Featuring Vishal Patel, MD, FAAD, FACMS | Associate Professor of Dermatology George Washington University School of Medicine & Health Sciences Washington, D.C. | Published October 17, 2025